Nov 2021: Den første kliniske utprøvingen av Sør-Koreas hjemmelagde neste generasjons chimeric antigen receptor T (CAR-T) celleterapi, som er utviklet for å omgå immunkontrollsignaler, har nylig kommet i gang.
Korea Advanced Institute of Science and Technology (KAIST) kunngjorde onsdag at en fase 1b klinisk studie av deres CAR-T-celleterapi for tiden gjennomføres ved Samsung Medical Center i Seoul. Forsøket gjennomføres med 10 koreanske pasienter som har residiverende og refraktært diffust stort B-celle lymfom. Markedsføringsrettighetene for rørledningen ble overført fra universitetet til selskapet Curocell, som ble medstiftet av professor Kim Chan-hyuk. Curocell er ansvarlig for det kliniske utviklingsprogrammet til revolusjonæren immunterapi.
In addition, a Phase 2 klinisk studie involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for kimær antigenreseptor T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Du vil kanskje lese: CAR T-Cell terapi i Korea
Resultatene av studien ble presentert i en artikkel som ble publisert på nettet i oktoberutgaven av Molecular Therapy.
